Signaturefd, LLC Kura Oncology, Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 2,086 shares of KURA stock, worth $18,169. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,086

Previous 5,278 60.48%

Holding current value

$18,169

Previous $108,000 62.96%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	SELL	$18.57 - $23.23 $59,275 - $74,150	-3,192 Reduced 60.48%	2,086 $40,000
Q2 2024 Jul 29, 2024	BUY	$17.53 - $22.98 $4,435 - $5,813	253 Added 5.03%	5,278 $108,000
Q1 2024 May 03, 2024	SELL	$13.42 - $23.53 $174 - $305	-13 Reduced 0.26%	5,025 $107,000
Q4 2023 Jan 31, 2024	BUY	$7.58 - $14.38 $10,983 - $20,836	1,449 Added 40.37%	5,038 $72,000
Q3 2023 Nov 03, 2023	BUY	$8.44 - $11.86 $1,451 - $2,039	172 Added 5.03%	3,589 $32,000
Q2 2023 Aug 01, 2023	BUY	$9.62 - $13.99 $1,577 - $2,294	164 Added 5.04%	3,417 $36,000
Q1 2023 Apr 28, 2023	BUY	$10.71 - $14.6 $3,448 - $4,701	322 Added 10.99%	3,253 $39,000
Q4 2022 Jan 27, 2023	BUY	$11.23 - $16.9 $123 - $185	11 Added 0.38%	2,931 $36,000
Q3 2022 Nov 08, 2022	BUY	$12.01 - $19.45 $396 - $641	33 Added 1.14%	2,920 $40,000
Q2 2022 Aug 10, 2022	SELL	$10.71 - $18.33 $1,713 - $2,932	-160 Reduced 5.25%	2,887 $53,000
Q1 2022 May 02, 2022	BUY	$11.78 - $16.98 $1,437 - $2,071	122 Added 4.17%	3,047 $49,000
Q4 2021 Jan 25, 2022	BUY	$12.22 - $19.57 $464 - $743	38 Added 1.32%	2,925 $41,000
Q4 2020 Feb 11, 2021	BUY	$29.0 - $41.62 $83,723 - $120,156	2,887 New	2,887 $94,000

Others Institutions Holding KURA

# of Institutions

185

Shares Held

81.8M

Call Options Held

42.1K

Put Options Held

34K

View Full List

About Kura Oncology, Inc.

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $583M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

More about KURA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account